ATE323088T1 - Bicyclische pyridin-und pyrimidinderivate als neuropeptid y rezeptorantagonisten - Google Patents
Bicyclische pyridin-und pyrimidinderivate als neuropeptid y rezeptorantagonistenInfo
- Publication number
- ATE323088T1 ATE323088T1 AT99906756T AT99906756T ATE323088T1 AT E323088 T1 ATE323088 T1 AT E323088T1 AT 99906756 T AT99906756 T AT 99906756T AT 99906756 T AT99906756 T AT 99906756T AT E323088 T1 ATE323088 T1 AT E323088T1
- Authority
- AT
- Austria
- Prior art keywords
- neuropeptide
- receptor antagonists
- pyrimidine derivatives
- bicyclic pyridine
- bicyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7398198P | 1998-02-06 | 1998-02-06 | |
US7392798P | 1998-02-06 | 1998-02-06 | |
US9348298P | 1998-07-20 | 1998-07-20 | |
US9357798P | 1998-07-20 | 1998-07-20 | |
US09/246,775 US6187777B1 (en) | 1998-02-06 | 1999-02-04 | Compounds and methods which modulate feeding behavior and related diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE323088T1 true ATE323088T1 (de) | 2006-04-15 |
Family
ID=27535987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99906756T ATE323088T1 (de) | 1998-02-06 | 1999-02-05 | Bicyclische pyridin-und pyrimidinderivate als neuropeptid y rezeptorantagonisten |
Country Status (13)
Country | Link |
---|---|
US (2) | US6187777B1 (de) |
EP (1) | EP1054887B1 (de) |
JP (1) | JP2003502272A (de) |
AT (1) | ATE323088T1 (de) |
AU (1) | AU747920B2 (de) |
CA (1) | CA2319275C (de) |
CY (1) | CY1105476T1 (de) |
DE (1) | DE69930835T2 (de) |
DK (1) | DK1054887T3 (de) |
ES (1) | ES2257851T3 (de) |
PT (1) | PT1054887E (de) |
SI (1) | SI1054887T1 (de) |
WO (1) | WO1999040091A1 (de) |
Families Citing this family (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1577816A3 (de) * | 1996-09-04 | 2006-08-02 | Intertrust Technologies Corp. | Vertrauenswürdige Infrastrukturbetreuungssysteme, Verfahren und Techniken zum sicheren elektronischen Handel und zur Rechteverwaltung |
ES2425559T5 (es) * | 1997-01-07 | 2018-02-02 | Amylin Pharmaceuticals, Llc | Composiciones farmacéuticas que comprenden las exendinas y los agonistas de las mismas |
WO1999024440A1 (en) | 1997-11-11 | 1999-05-20 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
CA2350714A1 (en) | 1998-11-10 | 2000-05-18 | Merck & Co., Inc. | Spiro-indolines as y5 receptor antagonists |
US6531475B1 (en) * | 1998-11-12 | 2003-03-11 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
IL142893A0 (en) | 1998-11-12 | 2002-04-21 | Neurocrine Biosciences Inc | Fused polyclic heterocyclic compounds and pharmaceutical compositions containing the same |
EP1165564B1 (de) * | 1999-04-08 | 2009-03-11 | Industrial Research Limited | Verfahren zur zubereitung von inhibitoren des nukleosid-metabolismus |
GB9915437D0 (en) | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
EP1214303A1 (de) * | 1999-08-31 | 2002-06-19 | Merck & Co., Inc. | Heterozyklische verbindungen und methode zu ihrer verwendung |
DE60026155T2 (de) * | 1999-09-30 | 2006-08-10 | Neurogen Corp., Branford | Einige alkylendiamin-substituierte heterocyclen |
CN1377355A (zh) * | 1999-09-30 | 2002-10-30 | 纽罗杰有限公司 | 氨基取代的吡唑并[1,5-a]-1,5-嘧啶和吡唑并[1,5-a]-1,3,5-三嗪 |
CN1377354A (zh) * | 1999-09-30 | 2002-10-30 | 纽罗杰有限公司 | 某些亚烷基二胺一取代的吡唑并[1,5-a]-1,5-嘧啶和吡唑并[1,5-a]-1,3,5-三嗪 |
AU2001263288A1 (en) * | 2000-05-18 | 2001-11-26 | Neurocrine Biosciences, Inc. | Crf receptor antagonists |
US7276492B2 (en) * | 2000-06-01 | 2007-10-02 | Kevorkian Robert C | Use of ACE inhibitors for treatment of patients suffering from behavioral disorders |
JP2004510736A (ja) * | 2000-10-03 | 2004-04-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アルコール中毒治療における神経ペプチドy拮抗物質の使用 |
US8564661B2 (en) | 2000-10-24 | 2013-10-22 | Objectvideo, Inc. | Video analytic rule detection system and method |
GB0100620D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical cokpounds V |
US20050226918A1 (en) * | 2001-08-13 | 2005-10-13 | Macdonald Stuart G | Delivery system for insulin and other therapeutic agents |
US6770652B2 (en) * | 2001-10-18 | 2004-08-03 | Duquesne University Of The Holy Ghost | Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same |
ES2193875B2 (es) | 2002-04-09 | 2005-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos. |
AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
TW200403243A (en) * | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
CN1835943B (zh) * | 2003-01-14 | 2012-03-07 | 阿伦纳药品公司 | 作为代谢调节剂的1,2,3-三取代的芳基和杂芳基衍生物及其应用 |
EP1927594A1 (de) | 2003-01-14 | 2008-06-04 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituierte Aryl- und Heteroarylderivate als Modulatoren des Metabolismus und zur Vorbeugung und Behandlung von Erkrankungen im Zusammenhang mit Diabetes und Hyperglykämie |
BRPI0406761A (pt) | 2003-01-14 | 2005-12-20 | Arena Pharm Inc | Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia |
CA2515963A1 (en) * | 2003-02-24 | 2004-09-10 | Arena Pharmaceuticals, Inc. | Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism |
ATE415390T1 (de) * | 2003-03-04 | 2008-12-15 | Addex Pharma Sa | Neue aminopyridinderivate als mglur5-antagonisten |
EP1615930A2 (de) | 2003-04-09 | 2006-01-18 | Biogen Idec MA, Inc. | Als a2a-adenosinrezeptor-antagonisten geeignete triazolotriazine und pyrazolotriazine |
EP1633756B1 (de) | 2003-04-09 | 2008-12-24 | Biogen Idec MA Inc. | A2a-adenosinrezeptorantagonisten |
EP1615931A1 (de) | 2003-04-09 | 2006-01-18 | Biogen Idec MA Inc. | Triazolopyrazine und verfahren zu deren herstellung und anwendung |
US7616233B2 (en) * | 2003-06-26 | 2009-11-10 | Fotonation Vision Limited | Perfecting of digital image capture parameters within acquisition devices using face detection |
AU2004259676A1 (en) * | 2003-07-10 | 2005-02-03 | Neurogen Corporation | Aryl-substituted benzo(d)isothiazol-3-ylamine analogues as capsaicin receptor modulators |
AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
ES2222833B1 (es) | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos. |
ZA200610669B (en) * | 2004-06-02 | 2008-06-25 | Takeda Pharmaceutical | Fused heterocyclic compound |
MEP8409A (en) | 2004-06-02 | 2011-12-20 | Fused heterocyclic compound | |
CN101870690A (zh) * | 2004-06-04 | 2010-10-27 | 艾尼纳制药公司 | 作为代谢调节剂的经取代芳基和杂芳基衍生物及其相关病症的预防和治疗 |
CA2573999A1 (en) * | 2004-07-16 | 2006-04-06 | Sunesis Pharmaceuticals, Inc. | Thienopyrimidines useful as aurora kinase inhibitors |
GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
US7674822B2 (en) | 2004-11-24 | 2010-03-09 | Wyeth | PTP1b inhibitors |
FR2878849B1 (fr) | 2004-12-06 | 2008-09-12 | Aventis Pharma Sa | Indoles substitues, compositions les contenant, procede de fabrication et utilisation |
MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
DOP2006000010A (es) | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
JP5463034B2 (ja) * | 2005-05-20 | 2014-04-09 | アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド | ピリミジン若しくはトリアジン縮合二環式メタロプロテアーゼ阻害薬 |
US20070155738A1 (en) * | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
KR101142363B1 (ko) * | 2005-06-27 | 2012-05-21 | 주식회사유한양행 | 피롤로피리딘 유도체를 포함하는 항암제 조성물 |
WO2007035355A2 (en) * | 2005-09-16 | 2007-03-29 | Arena Pharmaceuticals, Inc. | Modulators of metabolism and the treatment of disorders related thereto |
UY29825A1 (es) * | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones |
UY29823A1 (es) * | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones |
EP1961745A1 (de) | 2005-12-12 | 2008-08-27 | Ono Pharmaceutical Co., Ltd. | Bicyclische heterocyclische verbindung |
GB0608820D0 (en) * | 2006-05-04 | 2006-06-14 | Piramed Ltd | Pharmaceutical compounds |
TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
TW200811140A (en) * | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
TW200811147A (en) * | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
WO2008035195A1 (en) | 2006-09-21 | 2008-03-27 | Raqualia Pharma Inc. | Benzimidazole derivatives as selective acid pump inhibitors |
MX2009005950A (es) | 2006-12-07 | 2009-10-12 | Genentech Inc | Compuestos inhibidores de fosfoinositido 3-quinasas y metodos de uso. |
WO2008073785A2 (en) * | 2006-12-07 | 2008-06-19 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
WO2008082839A2 (en) * | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
US7893059B2 (en) | 2007-09-24 | 2011-02-22 | Genentech, Inc. | Thiazolopyrimidine PI3K inhibitor compounds and methods of use |
US8354528B2 (en) | 2007-10-25 | 2013-01-15 | Genentech, Inc. | Process for making thienopyrimidine compounds |
PL2215094T3 (pl) * | 2007-11-15 | 2016-09-30 | Związki heterocykliczne zawierające n | |
AR070454A1 (es) * | 2008-02-27 | 2010-04-07 | Nycomed Gmbh | Pirrolopirimidincarboxamidas y composiciones farmaceuticas que las comprenden |
MX2011001196A (es) * | 2008-07-31 | 2011-05-30 | Genentech Inc | Compuestos de pirimidina, composiciones y metodos de uso. |
UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
DE102008052943A1 (de) * | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
EP2405916B1 (de) | 2009-03-12 | 2018-02-07 | Genentech, Inc. | Kombination von phosphoinositid 3-kinase inhibitor- verbindungen und chemiotherapeutischen mitteln für die behandlung von blutbildenden bösartigen tumoren |
US8158625B2 (en) * | 2009-05-27 | 2012-04-17 | Genentech, Inc. | Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use |
SG175708A1 (en) * | 2009-05-27 | 2011-12-29 | Genentech Inc | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
EP2445346A4 (de) * | 2009-06-24 | 2012-12-05 | Genentech Inc | Oxoheterozyklische fusionierte pyrimidinverbindungen und -zusammensetzungen sowie verfahren zu ihrer verwendung |
AR077898A1 (es) * | 2009-08-26 | 2011-09-28 | Nycomed Gmbh | Metilpirrolopirimidincarboxamidas |
US8828990B2 (en) * | 2009-11-12 | 2014-09-09 | Genentech, Inc. | N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use |
MX2012005463A (es) * | 2009-11-12 | 2012-09-12 | Hoffmann La Roche | Compuestos de purina n/9 sustituida, composiciones y metodos de uso. |
JP5856980B2 (ja) | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ, インコーポレイテッド | (R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸およびその塩の調製のためのプロセス |
RU2012148699A (ru) | 2010-04-16 | 2014-05-27 | Дженентек, Инк. | Foxo3a как прогностический биомаркер для эффективности ингибитора пути киназы pi3k/акт |
SG187956A1 (en) * | 2010-08-27 | 2013-03-28 | Merck Patent Gmbh | Furopyridine derivatives |
PE20131371A1 (es) | 2010-09-22 | 2013-11-25 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este |
US20140004209A1 (en) | 2010-12-22 | 2014-01-02 | Genentech, Inc. | Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms |
DK2694484T3 (en) | 2011-04-08 | 2018-11-05 | Janssen Sciences Ireland Uc | PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS |
WO2013014052A1 (en) | 2011-07-22 | 2013-01-31 | Glaxosmithkline Llc | Composition |
DE102011111400A1 (de) * | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
PL2776439T3 (pl) | 2011-11-09 | 2018-12-31 | Janssen Sciences Ireland Uc | Pochodne puryny do leczenia zakażeń wirusowych |
CN104053661B (zh) | 2011-11-23 | 2018-06-19 | 癌症研究技术有限公司 | 非典型性蛋白激酶c的噻吩并嘧啶类抑制剂 |
US9045493B2 (en) * | 2012-02-09 | 2015-06-02 | Merck Patent Gmbh | Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives |
JP6097770B2 (ja) * | 2012-02-21 | 2017-03-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | フロピリジン誘導体 |
TW201414734A (zh) | 2012-07-10 | 2014-04-16 | Takeda Pharmaceutical | 氮雜吲哚衍生物 |
UA113651C2 (xx) | 2012-07-13 | 2017-02-27 | Макроциклічні пурини для лікування вірусних інфекцій | |
EP2888264B1 (de) | 2012-08-24 | 2017-09-27 | Glaxosmithkline LLC | Pyrazolopyrimidin-verbindungen |
PT2906563T (pt) | 2012-10-10 | 2018-05-23 | Janssen Sciences Ireland Uc | Derivados de pirrolo[3,2-d]pirimidina para o tratamento de infeções virais e outras doenças |
NZ748345A (en) | 2012-11-16 | 2020-04-24 | Janssen Sciences Ireland Uc | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
ES2632448T3 (es) | 2012-11-20 | 2017-09-13 | Glaxosmithkline Llc | Nuevos compuestos |
BR112015011439A2 (pt) | 2012-11-20 | 2017-07-11 | Glaxosmithkline Llc | composto, composição farmacêutica, composição de vacina, e, uso de um composto |
HUE13857477T2 (hu) | 2012-11-20 | 2018-05-28 | Glaxosmithkline Llc | Új vegyületek |
WO2014100071A2 (en) * | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted pyrrolopyrimidines as hdm2 inhibitors |
KR102225233B1 (ko) | 2013-02-21 | 2021-03-09 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체 |
WO2014130923A2 (en) | 2013-02-25 | 2014-08-28 | Genentech, Inc. | Methods and compositions for detecting and treating drug resistant akt mutant |
PT2978429T (pt) | 2013-03-29 | 2017-05-24 | Janssen Sciences Ireland Uc | Deaza-purinonas macrocíclicas para o tratamento de infeções virais |
EA034674B1 (ru) | 2013-05-24 | 2020-03-05 | Янссен Сайенсиз Айрлэнд Юси | Производные пиридона для лечения нарушений, в которое вовлечены модуляции tlr7 и/или tlr8 |
PL3030563T3 (pl) * | 2013-06-27 | 2018-01-31 | Janssen Sciences Ireland Uc | Pochodne pirolo [3,2-d] pirymidyny do leczenia zakażeń wirusowych i innych chorób |
EA036162B1 (ru) | 2013-07-30 | 2020-10-08 | Янссен Сайенсиз Айрлэнд Юси | Производные тиено[3,2-d]пиримидинов для лечения вирусных инфекций |
TW201620904A (zh) | 2014-01-09 | 2016-06-16 | 武田藥品工業有限公司 | 氮雜吲哚衍生物 |
CZ305472B6 (cs) * | 2014-04-30 | 2015-10-14 | Masarykova Univerzita | Substituované furo[3,2-b]pyridiny pro použití jako léčiva |
EP2940022B1 (de) | 2014-04-30 | 2020-09-02 | Masarykova Univerzita | Furopyridinen als Inhibitoren von Proteinkinasen |
GB201411236D0 (en) * | 2014-06-25 | 2014-08-06 | Takeda Pharmaceutical | Novel compounds |
CN107454899B (zh) | 2014-10-27 | 2020-05-29 | 大学健康网络 | Ripk2抑制剂及用其治疗癌症的方法 |
MX2017008925A (es) | 2015-01-06 | 2017-10-11 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
SG11201706307TA (en) | 2015-03-15 | 2017-09-28 | Sachem Inc | Structure directing agent for improved synthesis of zeolites |
HUE060476T2 (hu) | 2015-06-22 | 2023-03-28 | Arena Pharm Inc | (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra |
SG11201804901WA (en) | 2015-12-22 | 2018-07-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
CN109476675B (zh) | 2016-07-01 | 2022-12-09 | 爱尔兰詹森科学公司 | 用于治疗病毒性感染的二氢吡喃并嘧啶衍生物 |
JP7274415B2 (ja) | 2016-09-29 | 2023-05-16 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | ウイルス感染症および他の疾患を処置するためのピリミジンプロドラッグ |
WO2018151873A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
JP2020524703A (ja) | 2017-06-21 | 2020-08-20 | シャイ・セラピューティクス・エルエルシーShy Therapeutics Llc | がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのrasスーパーファミリーと相互作用する化合物 |
KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
CN111448190B (zh) | 2017-11-14 | 2023-09-26 | 百时美施贵宝公司 | 取代的吲哚化合物 |
US11878975B2 (en) | 2017-12-19 | 2024-01-23 | Bristol-Myers Squibb Company | Substituted indole compounds useful as TLR inhibitors |
WO2019126082A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | 6-azaindole compounds |
WO2019126081A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Amide substituted indole compounds useful as tlr inhibitors |
US11420958B2 (en) | 2017-12-20 | 2022-08-23 | Bristol-Myers Squibb Company | Aryl and heteroaryl substituted indole compounds |
CA3086431A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Amino indole compounds useful as tlr inhibitors |
ES2904773T3 (es) * | 2017-12-20 | 2022-04-06 | Bristol Myers Squibb Co | Compuestos de diazaindol |
TW201945003A (zh) | 2018-03-01 | 2019-12-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 2,4-二胺基喹唑啉衍生物及其醫學用途 |
EP3886854A4 (de) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrol- und pyrazolverbindungen und verfahren zu deren verwendung |
WO2020118183A1 (en) * | 2018-12-06 | 2020-06-11 | Kapoor Tarun M | 2,4-diaminopyrimidine bicycles for treating cancer |
CN114829362A (zh) * | 2019-12-10 | 2022-07-29 | 成都倍特药业股份有限公司 | 一种可用作shp2抑制剂的含氮杂原子的六元并五元芳环衍生物 |
WO2024017227A1 (zh) * | 2022-07-21 | 2024-01-25 | 长春金赛药业有限责任公司 | 取代的稠环大麻素受体化合物及其应用 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA907618A (en) | 1972-08-15 | Woitun Eberhard | 2-aminoalkylamino-thieno(3,2-d)pyrimidines and process for their production | |
BE754606A (fr) | 1969-08-08 | 1971-02-08 | Thomae Gmbh Dr K | Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication |
US3883651A (en) | 1969-08-08 | 1975-05-13 | Boehringer Sohn Ingelheim | Pharmaceutical compositions containing a 2-(aminoalkylamino)-4-amino-thieno{8 3,2-d{9 pyrimidine and method of use |
BE759493A (fr) | 1969-11-26 | 1971-05-25 | Thomae Gmbh Dr K | Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer |
US3763156A (en) | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
RO62428A (fr) | 1971-05-04 | 1978-01-15 | Thomae Gmbh Dr K | Procede pour la preparation des thyeno-(3,2-d)-pyrimidines |
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
US4731368A (en) | 1986-12-08 | 1988-03-15 | Merck & Co., Inc. | Thienopyridine sulfonamides and their ophthalmological formulation |
US4808595A (en) | 1986-12-24 | 1989-02-28 | Merck & Co., Inc. | Furopyridine sulfonamides and their opthalmological compositions |
JPH0527391A (ja) | 1991-07-23 | 1993-02-05 | Konica Corp | 新規な写真用カプラー |
FR2687402B1 (fr) | 1992-02-14 | 1995-06-30 | Lipha | Nouveaux azaindoles, procedes de preparation et medicaments les contenant. |
JP2895961B2 (ja) | 1992-12-17 | 1999-05-31 | フアイザー・インコーポレイテツド | Crfアンタゴニストとしてのピロロピリミジン |
WO1995010506A1 (en) | 1993-10-12 | 1995-04-20 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
US5461065A (en) | 1993-10-15 | 1995-10-24 | Eli Lilly And Company | Methods for inhibiting endometriosis |
US5441965A (en) | 1993-12-21 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting thrombin |
US5439923A (en) | 1993-12-21 | 1995-08-08 | Eli Lilly And Company | Method of inhibiting seborrhea and acne |
ES2109796T3 (es) | 1994-05-03 | 1998-01-16 | Ciba Geigy Ag | Derivados de pirrolopirimidilo con efecto antiproliferante. |
TW574214B (en) | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
US6075037A (en) | 1994-06-09 | 2000-06-13 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
KR100235277B1 (ko) | 1994-06-16 | 1999-12-15 | 디. 제이. 우드, 스피겔 알렌 제이 | 피라졸로- 및 피롤로-피리딘 |
US6562862B1 (en) | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
IL115613A0 (en) | 1994-10-20 | 1996-01-19 | Lilly Co Eli | Bicyclic neuropeptide y receptor antagonists |
PL321136A1 (en) | 1994-11-07 | 1997-11-24 | Pfizer | Some substituted derivatives of bencylamine as a new class of specific ligands of neuropeptide y1 |
EP0729758A3 (de) | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidine und Pyrrolopyrimidine zur Behandlung von neuronalen und anderen Krankheiten |
JPH10506126A (ja) | 1995-05-12 | 1998-06-16 | ニューロゲン コーポレイション | 新規なデアザプリン誘導体;crf1特異性リガンドの新規なクラス |
US5644057A (en) * | 1995-05-12 | 1997-07-01 | Neurogen Corporation | Deazapurine derivatives; a new class of CRF1 specific ligands |
WO1996040142A1 (en) | 1995-06-07 | 1996-12-19 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
FR2735777B1 (fr) * | 1995-06-21 | 1997-09-12 | Sanofi Sa | Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
AU7692896A (en) | 1995-12-01 | 1997-06-27 | Novartis Ag | Quinazolin-2,4-diazirines as NPY receptor antagonist |
AU7626496A (en) | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Heteroaryl compounds |
WO1997020821A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl derivatives |
AU7692996A (en) | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Receptor antagonists |
DE69628804T2 (de) | 1995-12-08 | 2003-12-18 | Pfizer | Substitutierte heterozyclische Derivate als CRF Antagonisten |
JP2000501107A (ja) | 1996-01-09 | 2000-02-02 | イーライ・リリー・アンド・カンパニー | ベンズイミダゾリル神経ペプチドy受容体アンタゴニスト |
DK0882051T3 (da) | 1996-02-07 | 2002-02-25 | Janssen Pharmaceutica Nv | Thiophenopyrimidiner |
US5688796A (en) | 1996-03-12 | 1997-11-18 | Eli Lilly And Company | Heterocyclic substituted benzothiophenes, compositions, and methods |
CA2249222C (en) | 1996-03-21 | 2005-11-08 | Banyu Pharmaceutical Co., Ltd. | Aminopyridine derivatives |
AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
DE69719193T2 (de) | 1996-08-06 | 2003-09-25 | Pfizer | Substituierte pyrido- oder pyrimidogruppen enthaltende 6,6- oder 6,7-bicyclische derivate |
WO1998006703A1 (en) | 1996-08-14 | 1998-02-19 | Warner-Lambert Company | 2-phenyl benzimidazole derivatives as mcp-1 antagonists |
PT938486E (pt) | 1996-08-23 | 2008-03-27 | Novartis Ag | Pirrolopirimidinas substituídas e processos para a sua preparação |
TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
BR9711970A (pt) | 1996-08-28 | 1999-08-24 | Pfizer | Derivados 6,5-substitu¡do-heterobic¡clicos |
EP0927166A1 (de) | 1997-02-14 | 1999-07-07 | Bayer Corporation | Amide als npy5-rezeptorantagonisten |
AU6144098A (en) | 1997-02-14 | 1998-09-08 | Bayer Corporation | Amide derivatives as selective neuropeptide y receptor antagonists |
ATE296825T1 (de) | 1997-08-05 | 2005-06-15 | Pfizer Prod Inc | 4-aminopyrrole(3,2-d)pyrimidine als neuropeptid rezeptor antagonisten |
-
1999
- 1999-02-04 US US09/246,775 patent/US6187777B1/en not_active Expired - Fee Related
- 1999-02-05 DK DK99906756T patent/DK1054887T3/da active
- 1999-02-05 AU AU26590/99A patent/AU747920B2/en not_active Ceased
- 1999-02-05 PT PT99906756T patent/PT1054887E/pt unknown
- 1999-02-05 ES ES99906756T patent/ES2257851T3/es not_active Expired - Lifetime
- 1999-02-05 CA CA002319275A patent/CA2319275C/en not_active Expired - Fee Related
- 1999-02-05 AT AT99906756T patent/ATE323088T1/de not_active IP Right Cessation
- 1999-02-05 EP EP99906756A patent/EP1054887B1/de not_active Expired - Lifetime
- 1999-02-05 JP JP2000530520A patent/JP2003502272A/ja not_active Withdrawn
- 1999-02-05 DE DE69930835T patent/DE69930835T2/de not_active Expired - Lifetime
- 1999-02-05 SI SI9930893T patent/SI1054887T1/sl unknown
- 1999-02-05 WO PCT/US1999/002500 patent/WO1999040091A1/en active IP Right Grant
-
2000
- 2000-08-16 US US09/640,263 patent/US6583154B1/en not_active Expired - Fee Related
-
2006
- 2006-07-06 CY CY20061100932T patent/CY1105476T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1054887A1 (de) | 2000-11-29 |
ES2257851T3 (es) | 2006-08-01 |
DE69930835D1 (de) | 2006-05-24 |
DE69930835T2 (de) | 2006-10-19 |
AU747920B2 (en) | 2002-05-30 |
JP2003502272A (ja) | 2003-01-21 |
EP1054887B1 (de) | 2006-04-12 |
CY1105476T1 (el) | 2010-07-28 |
DK1054887T3 (da) | 2006-05-08 |
WO1999040091A1 (en) | 1999-08-12 |
US6187777B1 (en) | 2001-02-13 |
US6583154B1 (en) | 2003-06-24 |
CA2319275C (en) | 2007-10-16 |
PT1054887E (pt) | 2006-06-30 |
AU2659099A (en) | 1999-08-23 |
CA2319275A1 (en) | 1999-08-12 |
SI1054887T1 (sl) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE323088T1 (de) | Bicyclische pyridin-und pyrimidinderivate als neuropeptid y rezeptorantagonisten | |
ID26984A (id) | Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda | |
DE69821132D1 (de) | 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes | |
ATE253039T1 (de) | Beta 2 -adrenergische rezeptor-agonisten | |
EA200100058A1 (ru) | 4-бензилпиперидиналкилсульфоксидные гетероциклические соединения и их применение в качестве подтип-избирательных антагонистов nmda-рецепторов | |
TR200000333T2 (tr) | Y alıcı antagonistleri olarak 4-aminopirol (3,2-d) pirimidinler. | |
TR200200408T2 (tr) | Yeni spiro bileşikleri | |
SE9702773D0 (sv) | Novel compounds | |
DE60214703D1 (de) | Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen | |
LU91758I2 (fr) | Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®) | |
DE60032249D1 (de) | AMINO-SUBSTITUIERTE PYRAZOLOi1,5-Aö-1,5-PYRIMIDINE UND PYRAZOLOi1,5-Aö-1,3,5-TRIAZINE | |
HK1083838A1 (en) | A2a adenosine receptor antagonists | |
EA200601160A1 (ru) | 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов | |
BR0209575A (pt) | Pirazinonas, piridinas e pirimidinas substituìdas como ligantes do fator liberador de corticotropina | |
DE60042066D1 (de) | Chimärische dr4 antikörper und ihre verwendung | |
MXPA04000886A (es) | Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos. | |
ES2184077T3 (es) | Nuevas fenantridinas sustituidas en la posicion 6. | |
TR199900318T2 (xx) | IL-8 resept�r antagonistleri. | |
ATE296809T1 (de) | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren | |
MXPA05011409A (es) | Composiciones y metodos para la terapia de enfermedad inflamatoria intestinal. | |
DE60023025D1 (de) | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren | |
ATE281439T1 (de) | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren | |
DK1196442T3 (da) | VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser | |
EA200000198A1 (ru) | 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов | |
TR199901380A2 (xx) | Di-ya da triazo-spiro$4,5] dekan t�revleri |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1054887 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |